Zonisamide - Drug Monograph

Introduction

Zonisamide is a sulfonamide-class antiepileptic drug (AED) used primarily as adjunctive therapy for focal (partial-onset) seizures in adults. It is also widely used off-label for generalized seizures, migraine prophylaxis, and weight loss in certain contexts. Its long half-life, broad-spectrum activity, and once-daily dosing make it a clinically versatile agent in neurology practice.

Drug Class and Overview

• Class: Antiepileptic drug; sulfonamide derivative; chemically distinct from other AEDs.
• Related agents: Other sodium-channel-blocking AEDs include carbamazepine, oxcarbazepine, lamotrigine, phenytoin, and lacosamide. Zonisamide is unique in combining sodium-channel blockade with T-type calcium-channel modulation and weak carbonic anhydrase inhibition.
• Distinguishing features: Long elimination half-life (~60–70 hours), broad-spectrum seizure coverage, and clinically meaningful weight loss as a frequent side effect.

Mechanism of Action

Zonisamide has multiple complementary mechanisms:

1. Blockade of voltage-gated sodium channels — reduces sustained repetitive neuronal firing by prolonging the inactivated state.
2. Reduction of voltage-dependent T-type calcium currents — relevant for its activity against generalized (especially absence) seizures.
3. Facilitation of dopaminergic and serotonergic neurotransmission — contributes to its effects on mood and possibly appetite.
4. Weak inhibition of carbonic anhydrase — contributes to the risk of metabolic acidosis and renal calculi.
5. Neuroprotective effects in experimental models, possibly via free-radical scavenging.

The combined effects stabilize neuronal membranes and suppress hypersynchronous epileptiform activity.

Indications

• FDA-approved: Adjunctive therapy in the treatment of partial-onset seizures in adults (Zonegran prescribing information).
• Off-label / evidence-supported uses:
• Adjunctive therapy for generalized tonic-clonic and other generalized seizure types.
• Migraine prophylaxis.
• Essential tremor (limited evidence).
• Weight loss (not FDA-approved for this indication; use is off-label and not recommended as primary therapy).

Dosage and Administration

• Adults (partial-onset seizures): Initiate at 100 mg orally once daily; may increase to 200 mg/day after 2 weeks. Further titration in increments of 100 mg every 2 weeks based on response, up to a typical maximum of 400 mg/day (some patients require up to 600 mg/day).
• Renal impairment: Use with caution in patients with CrCl < 50 mL/min; slower titration and closer monitoring recommended. Not removed by dialysis to a clinically meaningful extent.
• Hepatic impairment: Use with caution; no formal dose adjustment mandated, but monitor for adverse effects.
• Pediatric patients: Not FDA-approved in the United States for epilepsy; used in Japan and some other regions for pediatric seizures. Pediatric use carries heightened risk of oligohydrosis, hyperthermia, and serious dermatologic reactions.
• Geriatric patients: Initiate at the low end of the dosing range; monitor renal function and CNS adverse effects.
• Pregnancy: Use only if benefits outweigh risks; zonisamide has been associated with decreased birth weight and possible teratogenic risk in animal studies. Effective contraception is advised in women of childbearing potential.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed orally; peak plasma concentrations in 2–6 hours. Food delays absorption but does not reduce total exposure.
• Distribution: Approximately 40–50% protein-bound; crosses the blood–brain barrier and placenta.
• Metabolism: Undergoes hepatic metabolism via CYP3A4 (major), with additional contributions from N-acetylation and reduction. Not a strong inducer or inhibitor of CYP enzymes.
• Elimination: Excreted primarily in urine as metabolites and unchanged drug.
• Half-life: Approximately 60–70 hours in monotherapy; shortened to ~25–35 hours when co-administered with CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital).

Contraindications

• Known hypersensitivity to zonisamide, sulfonamides, or any component of the formulation.

Warnings and Precautions

• Serious dermatologic reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported, with higher incidence in pediatric patients and in patients with prior sulfonamide hypersensitivity. Discontinue immediately if rash develops.
• Metabolic acidosis: Hyperchloremic, non-anion-gap metabolic acidosis can occur due to carbonic anhydrase inhibition; risk increases with renal disease, severe respiratory disorders, diarrhea, or ketogenic diet. Baseline and periodic bicarbonate monitoring is recommended.
• Kidney stones: Reported in approximately 1–4% of patients; risk is higher with concurrent topiramate or acetazolamide, dehydration, or family history of nephrolithiasis.
• Oligohydrosis and hyperthermia: Predominantly reported in pediatric patients; counsel about heat exposure and ensure adequate hydration.
• Suicidal ideation and behavior: AEDs, including zonisamide, carry an FDA-class warning regarding increased risk of suicidal thoughts; monitor mood and behavior.
• Cognitive and psychiatric effects: Psychomotor slowing, word-finding difficulty, confusion, and rarely psychosis have been reported.
• Hematologic effects: Rare reports of aplastic anemia and agranulocytosis; discontinue if significant bone marrow suppression is suspected.
• Withdrawal seizures: Abrupt discontinuation may precipitate increased seizure frequency or status epilepticus; taper gradually.

Drug Interactions

• CYP3A4 inducers (carbamazepine, phenytoin, phenobarbital, rifampin, St. John's wort): Reduce zonisamide plasma concentrations; may require dose adjustment.
• Other carbonic anhydrase inhibitors (topiramate, acetazolamide): Additive risk of metabolic acidosis and nephrolithiasis.
• CNS depressants (alcohol, benzodiazepines, opioids, other sedating AEDs): Additive sedation, dizziness, and cognitive impairment.
• Oral contraceptives: No clinically significant pharmacokinetic interaction, but enzyme-inducing AEDs commonly co-administered may reduce contraceptive efficacy.
• Drugs affecting bicarbonate (e.g., chronic diuretics): May worsen metabolic acidosis.

Adverse Effects

Common (≥10%):

• Somnolence, dizziness, headache
• Anorexia, nausea, abdominal discomfort
• Weight loss
• Fatigue, ataxia
• Paresthesia, abnormal gait

Less common but clinically important:

• Cognitive impairment (word-finding difficulty, impaired concentration)
• Depression, anxiety, irritability, rare psychosis
• Diplopia, nystagmus
• Tremor

Serious / rare:

• Stevens-Johnson syndrome / TEN
• Aplastic anemia, agranulocytosis
• Metabolic acidosis
• Nephrolithiasis
• Oligohydrosis / hyperthermia (especially pediatric)
• Pancreatitis (rare)
• Rhabdomyolysis (rare)

Monitoring Parameters

• Baseline: Serum bicarbonate, renal function (BUN/creatinine), complete blood count, pregnancy test in women of childbearing potential.
• Ongoing: Periodic serum bicarbonate (every 3–6 months, more often if symptomatic), renal function, weight, mental status, and mood assessment.
• Clinical: Seizure frequency and severity, hydration status, signs of rash, cognitive complaints, and suicidal ideation.
• Pediatric-specific: Temperature regulation, sweating, hydration, especially during hot weather or illness.

Patient Education

• Take zonisamide exactly as prescribed; do not stop abruptly to avoid rebound seizures.
• Drink adequate fluids daily to reduce the risk of kidney stones and help prevent heat-related adverse effects.
• Report any skin rash, blistering, or mucosal lesions immediately.
• Report symptoms of metabolic acidosis: persistent fatigue, loss of appetite, rapid breathing, or confusion.
• Use effective contraception; discuss pregnancy planning with your clinician.
• Avoid alcohol and other CNS depressants unless specifically approved by your prescriber.
• Be cautious with driving or operating machinery until you know how the medication affects you.
• Monitor mood and report new or worsening depression, anxiety, or suicidal thoughts.

Clinical Pearls

1. Zonisamide's long half-life (~60–70 hours) allows once-daily dosing and produces stable plasma concentrations, but it also means adverse effects may persist for days after discontinuation.
2. The combination of sodium-channel blockade, T-type calcium-channel modulation, and carbonic anhydrase inhibition gives zonisamide a broad-spectrum profile useful in both focal and generalized epilepsies.
3. Weight loss is a frequent and sometimes desirable side effect, but it can become problematic in elderly or cachectic patients.
4. Always check serum bicarbonate — subclinical metabolic acidosis is common and easily missed without laboratory monitoring.
5. Co-administration with topiramate or acetazolamide substantially increases the risk of kidney stones and acidosis; avoid or monitor closely.
6. In pediatric patients, vigilance for oligohydrosis and hyperthermia is essential, particularly during summer months or febrile illness.

References

1. Eisai Inc. Zonegran (zonisamide) Capsules Prescribing Information. U.S. Food and Drug Administration.
2. U.S. Food and Drug Administration. Information for Healthcare Professionals: Suicidal Behavior and Ideation and Antiepileptic Drugs. FDA Drug Safety Communication.
3. Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Research.
4. Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure.
5. Glauser TA, et al. Efficacy and safety of zonisamide in pediatric and adult epilepsy. Epilepsia.
6. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Edition. Antiepileptic Drugs chapter.
7. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology, 15th Edition. Antiseizure Drugs chapter.
8. American Epilepsy Society. Clinical practice considerations for adjunctive antiseizure medications.
9. World Health Organization. WHO Model List of Essential Medicines (Antiseizure medicines section).
10. Lexicomp Online. Zonisamide: Drug Information. Wolters Kluwer Clinical Drug Information.